- Home
- ICLR vs INSM Comparison
ICLR vs INSM Comparison
Compare ICLR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- INSM
- Stock Information
- Founded
- ICLR 1990
- INSM 1988
- Country
- ICLR Ireland
- INSM United States
- Employees
- ICLR N/A
- INSM N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- ICLR Health Care
- INSM Health Care
- Exchange
- ICLR Nasdaq
- INSM Nasdaq
- Market Cap
- ICLR 11.5B
- INSM 12.6B
- IPO Year
- ICLR 1998
- INSM 2000
- Fundamental
- Price
- ICLR $133.96
- INSM $65.08
- Analyst Decision
- ICLR Buy
- INSM Strong Buy
- Analyst Count
- ICLR 12
- INSM 16
- Target Price
- ICLR $206.64
- INSM $95.36
- AVG Volume (30 Days)
- ICLR 2.1M
- INSM 2.5M
- Earning Date
- ICLR 04-30-2025
- INSM 05-08-2025
- Dividend Yield
- ICLR N/A
- INSM N/A
- EPS Growth
- ICLR 11.53
- INSM N/A
- EPS
- ICLR 9.19
- INSM N/A
- Revenue
- ICLR $8,192,621,999.00
- INSM $381,030,000.00
- Revenue This Year
- ICLR $1.63
- INSM $30.36
- Revenue Next Year
- ICLR $4.82
- INSM $115.55
- P/E Ratio
- ICLR $15.07
- INSM N/A
- Revenue Growth
- ICLR N/A
- INSM 20.77
- 52 Week Low
- ICLR $133.28
- INSM $21.92
- 52 Week High
- ICLR $347.72
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- ICLR 33.96
- INSM 35.80
- Support Level
- ICLR $135.00
- INSM $63.81
- Resistance Level
- ICLR $141.96
- INSM $73.39
- Average True Range (ATR)
- ICLR 6.69
- INSM 2.53
- MACD
- ICLR 0.43
- INSM -0.38
- Stochastic Oscillator
- ICLR 3.63
- INSM 13.26
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.